News
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...
STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
4d
GlobalData on MSNWeightWatchers shuns compounded semaglutide amid FDA rules
WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.
Through a trust, Dudum sold about $33.4 million worth of his company's stock on Thursday, according to a filing with the Securities and Exchange Commission put out after Monday's closing bell. The CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results